Objective analysis of standardized dermatological images
About the Project
The CE-certified Medical Device is the first technology to enable the generation, documentation, and objective analysis of standardized dermatological images using customizable analytical tools.
The system integrates the use of a small patch to standardize the imaging procedure and exchanges anonymized medical data in real time between users and a neuronal machine learning network. The product is supplied globally via SaaS to the biopharma and cosmetic industries, hospitals, physicians and their patients.
Opportunity symbolizes growth. We believe that all professionals should have the opportunity to create quality without having to invest in expensive and bulky devices: What allows Scarletred to be used by all types of industries, from young startups to multinational pharmaceuticals to academic institutions, is technology availability for everyone combined with its high scalability: a smartphone and an internet connection are the only requirements. This makes Scarletred®Vision a unique opportunity to seamlessly generate, manage, and analyze high-quality anonymized medical data on a global scale. This impacts in more efficient and safer dermatologic products as well as novel health care services faster at significant lower cost for everyone.
SCARLETRED is a Vienna based international digital health company revolutionising the global dermatology and telemedicine market. Our first product is the multi-award-winning Scarletred®Vision, a CE certified mobile medical device empowered by a proprietary artificial intelligence core. It is the first technology in the world which enables standardized dermatological imaging as well as remote and objective skin analysis for more than 3000 cutaneous conditions. With the start of the coronavirus pandemic in 2020, Scarletred®Vision gained a big momentum in the vaccination industry, which quickly adopted the new technology for the safety monitoring of Covid-19 injection site reactions. The company also rolled out the novel eCOVID19 mobile app and telemedicine platform to elderly care homes and drug stores for remote home-based health monitoring. SCARLETRED has been honored with, amongst other recognitions, the Austria State Prize “Digital Solutions”.
Partners: The development of our technology began with a clinical trial in breast cancer patients who had undergone radiation and chemotherapy and had consequently developed radiodermatitis, which at the time, could not be effectively documented, objectively quantified, and consequently its progression could not be followed over time. Together with the medical team at the University of Graz in Austria, we identified the technological requirements that were needed to solve these issues. Ever since, our Team has consistently been working on enhancing our technology to stay ahead of international medical requirements and ensure we offer state-of-the-art digital tools that assist doctors and experts in their assessment and diagnosis of dermatological conditions. We therefore thrive on working closely with health care services worldwide to understand their needs and offer them customized solutions.